Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9, which plays a key role in transcription regulation. This compound shows promise in oncology for targeting cancer cells by disrupting the transcriptional machinery necessary for tumor growth and survival. It has been investigated for its antiproliferative effects in hematological malignancies such as leukemia and lymphoma. Its structure allows for enhanced cellular penetration and sustained target inhibition, making it a candidate for development in targeted cancer therapies. Additionally, it serves as a molecular probe to study CDK-mediated signaling pathways in cellular models.